Compare Boston Scientific Corporation (BSX) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Invesco DB Commodity Index Tracking Fund — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while Invesco DB Commodity Index Tracking Fund trades at $29.97. The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | DBC | |
|---|---|---|
Market Cap | $71.46B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $108.14 | $31.69 |
52-Week Low | $42.63 | $21.62 |
Enterprise Value | $83.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
DBC trades at $28.91, up 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. Financial ratios are unavailable in the provided data. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.
The outlook for DBC is clouded by bearish technicals and lack of fundamental data. Commodity market volatility from geopolitical tensions offers potential upside, but investors face risks from unclear financial health and market sentiment shifts. Careful evaluation of upcoming earnings and analyst coverage is essential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
